Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 1, 2012, Pages 142-148

  Binkhathlan, Ziyad ^a,b   Shayeganpour, Anooshirvan ^a   Brocks, Dion R ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cyclosporine A; Doxorubicin; Pharmacokinetics; Polymeric micelle; Valspodar

Indexed keywords

CREMOPHOR; CYCLOSPORIN; CYCLOSPORIN A; DOXORUBICIN; DOXORUBICINOL; MACROGOL; METHOXYPOLY(ETHYLENE OXIDE); POLYCAPROLACTONE; UNCLASSIFIED DRUG; VALSPODAR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; ENCAPSULATION; EVAPORATION; MALE; NONHUMAN; RAT; REDUCTION; SINGLE DRUG DOSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CYCLOSPORINE; CYCLOSPORINS; DOXORUBICIN; DRUG INTERACTIONS; INJECTIONS, INTRAVENOUS; LACTONES; MALE; MICELLES; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SOLVENTS;

EID: 84861100996     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.02.003     Document Type: Article

References (51)

1. J.M. Ford, and W.N. Hait Pharmacology of drugs that alter multidrug resistance in cancer Pharmacol. Rev. 42 1990 155 199
2. K.V. Chin, I. Pastan, and M.M. Gottesman Function and regulation of the human multidrug resistance gene Adv. Cancer Res. 60 1993 157 180
3. R. Krishna, and L.D. Mayer Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur. J. Pharm. Sci. 11 2000 265 283
4. B.I. Sikic, G.A. Fisher, B.L. Lum, J. Halsey, L. Beketic-Oreskovic, and G. Chen Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein Cancer Chemother. Pharmacol. 40 Suppl. 1997 S13 19
5. M. Hirose Biology and modulation of multidrug resistance (MDR) in hematological malignancies Int. J. Hematol. 76 Suppl. 2 2002 206 211
6. D. Israeli, S. Ziaei, P. Gonin, and L. Garcia A proposal for the physiological significance of mdr1 and Bcrp1/Abcg2 gene expression in normal tissue regeneration and after cancer therapy J. Theor. Biol. 232 2005 41 45
7. N. Kartner, J.R. Riordan, and V. Ling Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines Science 221 1983 1285 1288
8. A. Sparreboom, and K. Nooter Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist. Updat. 3 2000 357 363
9. I.E. Kuppens, P. Breedveld, J.H. Beijnen, and J.H. Schellens Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application Cancer Invest. 23 2005 443 464
10. H.M. Coley Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors Methods Mol. Biol. 596 2010 341 358
11. S. Nobili, I. Landini, B. Giglioni, and E. Mini Pharmacological strategies for overcoming multidrug resistance Curr. Drug Targets 7 2006 861 879
12. F. Loor Valspodar: current status and perspectives Expert Opin. Investig. Drugs 8 1999 807 835
13. V. Fischer, A. Rodriguez-Gascon, F. Heitz, R. Tynes, C. Hauck, D. Cohen, and A.E. Vickers The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite Drug Metab. Dispos. 26 1998 802 811
14. K.T. Kivisto, H.K. Kroemer, and M. Eichelbaum The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions Br. J. Clin. Pharmacol. 40 1995 523 530
15. S. Song, H. Suzuki, R. Kawai, and Y. Sugiyama Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats Drug Metab. Dispos. 27 1999 689 694
16. K.V. Speeg, and A.L. Maldonado Effect of the nonimmuno suppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo Cancer Chemother. Pharmacol. 34 1994 133 136
17. M. Achira, H. Suzuki, K. Ito, and Y. Sugiyama Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4 AAPS PharmSci. 1 1999 E18
18. J.E. Kolitz, S.L. George, G. Marcucci, R. Vij, B.L. Powell, S.L. Allen, D.J. DeAngelo, T.C. Shea, W. Stock, M.R. Baer, V. Hars, K. Maharry, E. Hoke, J.W. Vardiman, C.D. Bloomfield, and R.A. Larson P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 Blood 116 2010 1413 1421
19. M.M. O'Brien, N.J. Lacayo, B.L. Lum, S. Kshirsagar, S. Buck, Y. Ravindranath, M. Bernstein, H. Weinstein, M.N. Chang, R.J. Arceci, B.I. Sikic, and G.V. Dahl Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group Pediatr. Blood Cancer 54 2010 694 702
20. H.M. Aliabadi, D.R. Brocks, and A. Lavasanifar Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution Biomaterials 26 2005 7251 7259
21. H.M. Aliabadi, D.R. Brocks, P. Mahdipoor, and A. Lavasanifar A novel use of an in vitro method to predict the in vivo stability of block copolymer based nano-containers J. Control Release 122 2007 63 70
22. Z. Binkhathlan, D.A. Hamdy, D.R. Brocks, and A. Lavasanifar Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat Eur. J. Pharm. Biopharm. 75 2010 90 95
23. S.V. Kanduru, V. Somayaji, A. Lavasanifar, and D.R. Brocks An analytical method for cyclosporine using liquid chromatography-mass spectrometry Biomed. Chromatogr. 24 2010 148 153
24. H.M. Aliabadi, A. Mahmud, A.D. Sharifabadi, and A. Lavasanifar Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A J. Control Release 104 2005 301 311
25. D.R. Brocks Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug Biopharm. Drug Dispos. 21 2000 365 371
26. W.L. Chiou Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve J. Pharmacokinet. Biopharm. 6 1978 539 546
27. O. Gonzalez, T. Colombo, M. De Fusco, L. Imperatori, M. Zucchetti, and M. D'Incalci Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833 Cancer Chemother. Pharmacol. 36 1995 335 340
28. R. Krishna, M. St-Louis, and L.D. Mayer Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin Int. J. Cancer 85 2000 131 141
29. A.R. Goeptar, J.M. Te Koppele, E.K. Lamme, J.M. Pique, and N.P. Vermeulen Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes Mol. Pharmacol. 44 1993 1267 1277
30. B.J. Cusack, S.P. Young, J. Driskell, and R.D. Olson Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit Cancer Chemother. Pharmacol. 32 1993 53 58
31. C.E. Riggs Jr., R.S. Benjamin, A.A. Serpick, and N.R. Bachur Biliary disposition of adriamycin Clin. Pharmacol. Ther. 22 1977 234 241
32. N. Tavoloni, and A.M. Guarino Biliary and urinary excretion of adriamycin in anesthetized rats Pharmacology 20 1980 256 267
33. D.W. Yesair, E. Schwartzbach, D. Shuck, E.P. Denine, and M.A. Asbell Comparative pharmacokinetics of daunomycin and adriamycin in several animal species Cancer Res. 32 1972 1177 1183
34. F. Ballet, P. Vrignaud, and J. Robert Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver Cancer Chemother. Pharmacol. 19 1987 240 245
35. T. Colombo, M. Zucchetti, and M. D'Incalci Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats J. Pharmacol. Exp. Ther. 269 1994 22 27
36. K.V. Speeg, A.L. Maldonado, J. Liaci, and D. Muirhead Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo Hepatology 15 1992 899 903
37. K.V. Speeg, A.L. Maldonado, J. Liaci, and D. Muirhead Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo J. Pharmacol. Exp. Ther. 261 1992 50 55
38. T. Suzuki, Y.L. Zhao, M. Nadai, K. Naruhashi, A. Shimizu, K. Takagi, K. Takagi, and T. Hasegawa Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats Life Sci. 79 2006 455 461
39. M.L. Vlaming, K. Mohrmann, E. Wagenaar, D.R. de Waart, R.P. Elferink, J.S. Lagas, O. van Tellingen, L.D. Vainchtein, H. Rosing, J.H. Beijnen, J.H. Schellens, and A.H. Schinkel Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice J. Pharmacol. Exp. Ther. 318 2006 319 327
40. S. Yamaguchi, Y.L. Zhao, M. Nadai, H. Yoshizumi, X. Cen, S. Torita, K. Takagi, K. Takagi, and T. Hasegawa Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport Antimicrob. Agents Chemother. 50 2006 80 87
41. M. Qadir, K.L. O'Loughlin, S.M. Fricke, N.A. Williamson, W.R. Greco, H. Minderman, and M.R. Baer Cyclosporin A is a broad-spectrum multidrug resistance modulator Clin. Cancer Res. 11 2005 2320 2326
42. A. Aszalos, K. Thompson, J.J. Yin, and D.D. Ross Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp) Anticancer Res. 19 1999 1053 1064
43. D.M. Woodcock, S. Jefferson, M.E. Linsenmeyer, P.J. Crowther, G.M. Chojnowski, B. Williams, and I. Bertoncello Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs Cancer Res. 50 1990 4199 4203
44. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598
45. L.K. Webster, E.J. Cosson, K.H. Stokes, and M.J. Millward Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice Br. J. Cancer 73 1996 522 524
46. R. Krishna, N. McIntosh, K.W. Riggs, and L.D. Mayer Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion Clin. Cancer Res. 5 1999 2939 2947
47. R. Krishna, and L.D. Mayer Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors Cancer Res. 57 1997 5246 5253
48. V. Torchilin Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Deliv. Rev. 63 2011 131 135
49. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 41 2001 189 207
50. H. Maeda, J. Fang, T. Inutsuka, and Y. Kitamoto Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications Int. Immunopharmacol. 3 2003 319 328
51. H. Maeda, Y. Noguchi, K. Sato, and T. Akaike Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor Jpn. J. Cancer Res. 85 1994 331 334